NASDAQ · Biotechnology · USD
Black Diamond Therapeutics, Inc. (BDTX) Stock Analysis
Black Diamond Therapeutics, Inc. (BDTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BDTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.07
- Previous Close
- $2.07
- Day's Range
- 2.01–2.14
- 52-Week Range
- 1.60–4.94
- Volume
- 2.36M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 3.33
Valuation
- Market Cap
- $118.61M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.75
Financials (FY)
- Revenue (FY)
- $70.00M
- Net Income (FY)
- $22.37M
- Shares Outstanding
- 57.30M
- 1-Year Return
- −47.47%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 615.44K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, BDTX closed at $2.08, −47.47% over 1 year.
Black Diamond Therapeutics, Inc. (BDTX) has a market capitalization of $118.61M.
In fiscal 2025, BDTX reported revenue of $70.00M.
BDTX Stock Return by Calendar Year
Black Diamond Therapeutics, Inc. (BDTX) return since Jan 2020: what $10,000 became
- 1 year
- $10,000 $5,253
- −47.47%
- 5 years
- $10,000 $2,558
- −74.42%
- Since Jan 2020
- $10,000 $555
- −94.45%
If you had invested $10,000 in Black Diamond Therapeutics, Inc. (BDTX) at the close on January 31, 2020, the earliest close on record here, it would have been worth $555 at the close on October 21, 2026: −94.45% in total, −34.97% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −14.40% |
| 2025 | +13.55% |
| 2024 | −23.84% |
| 2023 | +56.11% |
| 2022 | −66.23% |
| 2021 | −83.37% |
| 2020 | −14.53% |
As of October 21, 2026.
BDTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $70.00M | $22.37M | 32.0% |
| 2024 | $0.00 | −$69.68M | — |
| 2023 | $0.00 | −$82.44M | — |
| 2022 | $0.00 | −$91.17M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $70.00M | — | $19.87M | $22.37M | 32.0% |
| 2024 | $0.00 | — | −$78.78M | −$69.68M | — |
| 2023 | $0.00 | — | −$86.46M | −$82.44M | — |
| 2022 | $0.00 | — | −$92.83M | −$91.17M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
YahooBlack Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
YahooBlack Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B